Il1rn (interleukin 1 receptor antagonist) - Rat Genome Database

Send us a Message

Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Il1rn (interleukin 1 receptor antagonist) Rattus norvegicus
Symbol: Il1rn
Name: interleukin 1 receptor antagonist
RGD ID: 621159
Description: Enables interleukin-1 receptor binding activity. Involved in several processes, including cellular response to norepinephrine stimulus; chronic inflammatory response to antigenic stimulus; and fever generation. Located in extracellular space. Used to study adult respiratory distress syndrome; anti-basement membrane glomerulonephritis; hypertension; silicosis; and transient cerebral ischemia. Biomarker of encephalitis and pneumonia. Human ortholog(s) of this gene implicated in several diseases, including autoimmune disease (multiple); eye disease (multiple); kidney failure (multiple); lung disease (multiple); and vascular disease (multiple). Orthologous to human IL1RN (interleukin 1 receptor antagonist); PARTICIPATES IN interleukin-1 signaling pathway; INTERACTS WITH (S)-nicotine; 15-deoxy-Delta(12,14)-prostaglandin J2; 17alpha-ethynylestradiol.
Type: protein-coding
Previously known as: IL-1ra; IL-1RN; IL1 inhibitor; interleukin 1 receptor antagonist gene; interleukin-1 receptor antagonist protein; IRAP
RGD Orthologs
Green Monkey
Naked Mole-Rat
Alliance Genes
More Info more info ...
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Rat AssemblyChrPosition (strand)SourceGenome Browsers
mRatBN7.237,111,567 - 7,127,451 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl37,111,550 - 7,127,445 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx310,225,656 - 10,231,090 (+)NCBIRnor_SHR
UTH_Rnor_SHRSP_BbbUtx_1.0318,811,887 - 18,817,327 (+)NCBIRnor_SHRSP
UTH_Rnor_WKY_Bbb_1.0317,001,698 - 17,007,132 (+)NCBIRnor_WKY
Rnor_6.031,449,778 - 1,468,624 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl31,452,644 - 1,468,614 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.031,445,598 - 1,461,452 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.432,607,800 - 2,613,216 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.132,607,803 - 2,611,842 (+)NCBI
Celera31,959,290 - 1,964,693 (+)NCBICelera
Cytogenetic Map3p13NCBI
JBrowse: View Region in Genome Browser (JBrowse)

Disease Annotations     Click to see Annotation Detail View
Abscess  (ISO)
acute kidney failure  (ISO)
Acute Liver Failure  (ISO)
Acute Lung Injury  (IEP,IMP)
acute necrotizing pancreatitis  (ISO)
adult respiratory distress syndrome  (IDA,ISO)
allergic conjunctivitis  (ISO)
alopecia areata  (ISO)
Anorexia  (IEP,ISO)
anterior uveitis  (ISO)
anthracosis  (ISO)
anti-basement membrane glomerulonephritis  (IDA)
Arsenic Poisoning  (ISO)
asthma  (ISO)
Atrophy  (ISO)
autistic disorder  (ISO)
autoimmune thrombocytopenic purpura  (ISO)
autosomal dominant polycystic kidney disease  (ISO)
B-Cell Chronic Lymphocytic Leukemia  (ISO)
bacterial pneumonia  (ISO)
Behcet's disease  (ISO)
Brain Injuries  (ISO)
brain ischemia  (ISO)
Bronchial Hyperreactivity  (ISO)
bronchiolitis  (ISO)
bronchiolitis obliterans  (ISO)
bronchopulmonary dysplasia  (ISO)
bronchus carcinoma  (ISO)
Cachexia  (IDA)
calcium oxalate nephrolithiasis  (ISO)
cardiovascular system disease  (ISO)
Carotid Artery Injuries  (ISO)
Cerebral Hemorrhage  (IEP,ISO)
cerebrovascular disease  (ISO)
Chediak-Higashi syndrome  (ISO)
Chronic Anterior Uveitis  (ISO)
chronic kidney disease  (ISO)
chronic myeloid leukemia  (ISO)
chronic obstructive pulmonary disease  (ISO)
Chronic Rhinosinusitis  (ISO)
Chronic Uveitis  (ISO)
cicatricial pemphigoid  (ISO)
Colonic Neoplasms  (ISO)
common cold  (ISO)
Corneal Graft Rejection  (ISO)
corneal neovascularization  (ISO)
crescentic glomerulonephritis  (ISO)
Cryopyrin-Associated Periodic Syndromes  (ISO)
cystic fibrosis  (ISO)
dacryocystitis  (ISO)
Deficiency of Interleukin-1 Receptor Antagonist  (ISO)
depressive disorder  (ISO)
diabetic angiopathy  (ISO)
Diabetic Nephropathies  (ISO)
diarrhea  (ISO)
Drug Hypersensitivity Syndrome  (ISO)
Drug-Induced Agranulocytosis  (ISO)
Drug-Related Side Effects and Adverse Reactions  (ISO)
dry eye syndrome  (ISO)
encephalitis  (IEP)
end stage renal disease  (ISO)
endometriosis  (ISO)
Endotoxemia  (IEP,ISO)
Endotoxin-Induced Uveitis  (IEP,ISO)
exanthem  (ISO)
Experimental Arthritis  (IEP,ISO)
Experimental Autoimmune Encephalomyelitis  (ISO)
Experimental Autoimmune Myocarditis  (ISO)
Experimental Autoimmune Uveitis  (ISO)
Experimental Colitis  (ISO)
Experimental Diabetes Mellitus  (ISO)
Experimental Mammary Neoplasms  (ISO)
Extravasation of Diagnostic and Therapeutic Materials  (ISO)
Eye Manifestations  (ISO)
Febrile Seizures  (ISO)
Fever  (IDA,ISO)
fibromyalgia  (ISO)
Fibrosis  (ISO)
genetic disease  (ISO)
glomerulonephritis  (ISO)
gout  (ISO)
graft-versus-host disease  (ISO)
Graves ophthalmopathy  (ISO)
hairy cell leukemia  (ISO)
hemolytic-uremic syndrome  (ISO)
Henoch-Schoenlein purpura  (ISO)
hepatocellular carcinoma  (ISO)
herpes simplex virus keratitis  (ISO)
Human Influenza  (ISO)
Hyperalgesia  (IDA,IMP,ISO)
hyperglycemia  (ISO)
hypertension  (IDA,ISO)
idiopathic pulmonary fibrosis  (ISO)
IgA glomerulonephritis  (ISO)
Inflammation  (IEP,ISO)
inflammatory bowel disease  (ISO)
interstitial lung disease  (ISO)
juvenile rheumatoid arthritis  (ISO)
keratoconus  (ISO)
kidney disease  (ISO)
Kidney Reperfusion Injury  (ISO)
learning disability  (ISO)
Leukocytosis  (ISO)
Lichen Sclerosus et Atrophicus  (ISO)
listeriosis  (ISO)
Liver Reperfusion Injury  (IMP,ISO)
lung non-small cell carcinoma  (ISO)
lupus nephritis  (ISO)
Meibomian Gland Dysfunction  (ISO)
melanoma  (ISO)
middle cerebral artery infarction  (ISO)
morbid obesity  (ISO)
Muckle-Wells syndrome  (ISO)
mucositis  (ISO)
multiple myeloma  (ISO)
Multiple Organ Failure  (ISO)
multiple sclerosis  (ISO)
myocardial infarction  (ISO)
Myocardial Reperfusion Injury  (ISO)
myositis  (ISO)
Necrosis  (ISO)
Neoplasm Invasiveness  (ISO)
nephrotic syndrome  (ISO)
non-alcoholic fatty liver disease  (ISO)
obesity  (ISO)
Oligoanuria  (ISO)
osteoporosis  (ISO)
Pain  (ISO)
periodontitis  (ISO)
pleural disease  (ISO)
pleural tuberculosis  (ISO)
pleurisy  (ISO)
pneumonia  (IEP,ISO)
Postoperative Cognitive Dysfunction  (ISO)
pre-eclampsia  (ISO)
Proctocolitis  (ISO)
Prostatic Neoplasms  (ISO)
prostatitis  (ISO)
proteinuria  (ISO)
Pseudomonas Aeruginosa Keratitis  (ISO)
Pseudomonas Infections  (ISO)
pulmonary eosinophilia  (ISO)
pulmonary fibrosis  (ISO)
pulmonary hypertension  (ISO)
pulmonary sarcoidosis  (ISO)
pulmonary tuberculosis  (ISO)
pustular psoriasis 14  (ISO)
pyelonephritis  (ISO)
renal cell carcinoma  (ISO)
respiratory allergy  (ISO)
rheumatoid arthritis  (ISO)
rhinitis  (ISO)
Schnitzler syndrome  (ISO)
sciatic neuropathy  (ISO)
Sclerosis  (ISO)
Sepsis  (IEP,ISO)
Serositis  (ISO)
silicosis  (IDA,ISO)
Sjogren's syndrome  (ISO)
skin disease  (ISO)
Spinal Cord Injuries  (IDA,ISO)
status epilepticus  (ISO)
stomach cancer  (ISO)
Stomach Neoplasms  (ISO)
Stroke  (ISO)
Subarachnoid Hemorrhage  (ISO)
systemic lupus erythematosus  (ISO)
Tobacco Use Disorder  (ISO)
toxic shock syndrome  (ISO)
transient cerebral ischemia  (IDA,ISO)
Transplant Rejection  (ISO)
type 1 diabetes mellitus  (ISO)
type 2 diabetes mellitus  (ISO)
ulcerative colitis  (ISO)
ureteral obstruction  (ISO)
urinary bladder cancer  (ISO)
Urinary Calculi  (ISO)
vascular disease  (ISO)
Venous Thrombosis  (ISO)
Ventilator-Induced Lung Injury  (IEP)
Viral Bronchiolitis  (ISO)
viral pneumonia  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(1->4)-beta-D-glucan  (ISO)
(S)-nicotine  (EXP)
1,1-dichloroethene  (ISO)
1,2-dimethylhydrazine  (ISO)
15-deoxy-Delta(12,14)-prostaglandin J2  (EXP)
17alpha-ethynylestradiol  (EXP)
17beta-estradiol  (EXP,ISO)
17beta-estradiol 3-benzoate  (EXP)
2,2',4,4',5,5'-hexachlorobiphenyl  (ISO)
2,2',5,5'-tetrachlorobiphenyl  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,4,6-trinitrobenzenesulfonic acid  (EXP)
3',5'-cyclic AMP  (ISO)
3,3',4,4',5-pentachlorobiphenyl  (ISO)
3,3',5,5'-tetrabromobisphenol A  (ISO)
3,4-dichloroaniline  (ISO)
3,5-diethoxycarbonyl-1,4-dihydrocollidine  (ISO)
3,7-dihydropurine-6-thione  (EXP)
4-hydroxynon-2-enal  (ISO)
4-hydroxyphenyl retinamide  (ISO)
5-fluorouracil  (ISO)
6alpha-methylprednisolone  (ISO)
7,12-dimethyltetraphene  (ISO)
7-ketocholesterol  (ISO)
acetamide  (EXP)
acetylcholine  (ISO)
acetylsalicylic acid  (ISO)
aflatoxin B1  (EXP,ISO)
Aflatoxin B2 alpha  (ISO)
aldehydo-D-glucose  (EXP)
alendronic acid  (EXP)
all-trans-retinoic acid  (ISO)
all-trans-retinyl palmitate  (ISO)
alpha-naphthoflavone  (ISO)
aluminium hydroxide  (ISO)
ammonium chloride  (EXP)
antimonite  (ISO)
antirheumatic drug  (ISO)
arsane  (EXP,ISO)
arsenic atom  (EXP,ISO)
arsenite(3-)  (ISO)
arsenous acid  (ISO)
astressin  (EXP)
azathioprine  (ISO)
beclomethasone  (ISO)
benzene  (ISO)
benzo[a]pyrene  (ISO)
beta-endorphin  (EXP)
beta-naphthoflavone  (ISO)
bis(2-chloroethyl) sulfide  (ISO)
bisphenol A  (EXP,ISO)
cadmium atom  (ISO)
cadmium dichloride  (EXP,ISO)
calcitriol  (ISO)
capsaicin  (EXP)
carbon nanotube  (ISO)
carvedilol  (EXP)
celastrol  (ISO)
ceric oxide  (EXP)
cholesterol  (ISO)
choline  (ISO)
cisplatin  (ISO)
cobalt dichloride  (ISO)
copper(II) sulfate  (ISO)
crocidolite asbestos  (ISO)
cyclophosphamide  (ISO)
cyclosporin A  (ISO)
D-glucose  (EXP)
delta-tocotrienol  (ISO)
deoxynivalenol  (ISO)
dexamethasone  (ISO)
dextran sulfate  (ISO)
diarsenic trioxide  (ISO)
dichloroacetic acid  (ISO)
dichloromethane  (ISO)
diclofenac  (ISO)
dicrotophos  (ISO)
dioxygen  (EXP,ISO)
dipotassium bis[mu-tartrato(4-)]diantimonate(2-) trihydrate  (ISO)
diuron  (ISO)
doxorubicin  (EXP)
elemental selenium  (ISO)
endosulfan  (EXP)
epoxiconazole  (ISO)
erlotinib hydrochloride  (ISO)
ethanol  (ISO)
folic acid  (ISO)
fumonisin B1  (ISO)
gedunin  (ISO)
Genipin  (ISO)
genistein  (ISO)
gentamycin  (EXP)
glafenine  (EXP)
glucose  (EXP)
glycidol  (EXP)
graphene oxide  (ISO)
graphite  (EXP)
hydroquinone  (ISO)
ibuprofen  (EXP,ISO)
indometacin  (ISO)
ionomycin  (ISO)
iron(2+) sulfate (anhydrous)  (ISO)
isoliquiritigenin  (ISO)
isoprenaline  (ISO)
ivermectin  (ISO)
L-methionine  (ISO)
lead diacetate  (EXP,ISO)
leflunomide  (ISO)
lenalidomide  (ISO)
lipopolysaccharide  (EXP,ISO)
malonaldehyde  (ISO)
manganese(II) chloride  (EXP)
mercaptopurine  (EXP)
mercury dichloride  (ISO)
metformin  (ISO)
methacholine chloride  (ISO)
methapyrilene  (EXP)
methotrexate  (ISO)
methylmercury chloride  (EXP)
methyltestosterone  (ISO)
Mofezolac (TN)  (ISO)
morphine  (ISO)
N-methyl-4-phenylpyridinium  (ISO)
N-nitrosodiethylamine  (ISO)
nickel atom  (ISO)
nickel sulfate  (ISO)
nicotine  (EXP)
oxaliplatin  (EXP)
ozone  (ISO)
p-chloromercuribenzoic acid  (ISO)
paracetamol  (EXP,ISO)
paraquat  (EXP,ISO)
paricalcitol  (ISO)
pentane-2,3-dione  (EXP)
perfluorooctane-1-sulfonic acid  (ISO)
perfluorooctanoic acid  (ISO)
phloretin  (ISO)
phorbol 13-acetate 12-myristate  (ISO)
phosphorus atom  (ISO)
phosphorus(.)  (ISO)
pirinixic acid  (EXP,ISO)
piroxicam  (ISO)
potassium dichromate  (ISO)
prednisolone  (ISO)
pregnenolone 16alpha-carbonitrile  (ISO)
progesterone  (EXP)
prostaglandin E2  (ISO)
purine-6-thiol  (EXP)
quercetin  (ISO)
resveratrol  (EXP,ISO)
rofecoxib  (ISO)
rotenone  (ISO)
scopolamine  (ISO)
selenium atom  (ISO)
serpentine asbestos  (ISO)
silicon dioxide  (EXP,ISO)
silver atom  (ISO)
silver(0)  (ISO)
sodium arsenite  (EXP,ISO)
sodium aurothiomalate  (ISO)
sodium fluoride  (EXP)
Soman  (ISO)
streptozocin  (ISO)
succimer  (ISO)
sulfasalazine  (EXP)
tacrolimus hydrate  (ISO)
testosterone  (EXP)
tetrachloroethene  (ISO)
tetrachloromethane  (ISO)
thalidomide  (ISO)
thioacetamide  (EXP)
titanium dioxide  (ISO)
topotecan  (EXP)
tremolite asbestos  (ISO)
trichloroethene  (ISO)
trimellitic anhydride  (ISO)
trimethyltin  (ISO)
urethane  (ISO)
wortmannin  (ISO)
zinc atom  (ISO)
zinc dichloride  (ISO)
zinc oxide  (EXP)
zinc(0)  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Cellular Component
extracellular region  (ISO)
extracellular space  (IBA,IDA,IEA,ISO)
vesicle  (ISO)

Molecular Pathway Annotations     Click to see Annotation Detail View

References - curated
# Reference Title Reference Citation
1. Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans. null
2. Association of interleukin-1A, interleukin-1B and interleukin-1 receptor antagonist gene polymorphisms with multiple myeloma. Abazis-Stamboulieh D, etal., Leuk Lymphoma. 2007 Nov;48(11):2196-203.
3. Association of low-grade inflammation with nephropathy in type 2 diabetic patients: role of elevated CRP-levels and 2 different gene-polymorphisms of proinflammatory cytokines. Abrahamian H, etal., Exp Clin Endocrinol Diabetes. 2007 Jan;115(1):38-41.
4. Genetic association of interleukin-1beta (-511C/T) and interleukin-1 receptor antagonist (86 bp repeat) polymorphisms with Type 2 diabetes mellitus in North Indians. Achyut BR, etal., Clin Chim Acta. 2007 Feb;377(1-2):163-9. Epub 2006 Oct 27.
5. Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapy. Ahirwar DK, etal., Biomarkers. 2009 Jun;14(4):213-8.
6. ANG II receptor blockade enhances anti-inflammatory macrophages in anti-glomerular basement membrane glomerulonephritis. Aki K, etal., Am J Physiol Renal Physiol. 2010 Apr;298(4):F870-82. Epub 2010 Jan 13.
7. Suppression of monocyte function and differential regulation of IL-1 and IL-1ra by IL-4 contribute to resolution of experimental arthritis. Allen JB, etal., J Immunol. 1993 Oct 15;151(8):4344-51.
8. Chronic inhibition of endoplasmic reticulum stress and inflammation prevents ischaemia-induced vascular pathology in type II diabetic mice. Amin A, etal., J Pathol. 2012 Jun;227(2):165-74. doi: 10.1002/path.3960. Epub 2012 Feb 17.
9. Interleukin 1 receptor antagonist gene polymorphism is associated with severe renal involvement and renal sequelae in Henoch-Schonlein purpura. Amoli MM, etal., J Rheumatol. 2002 Jul;29(7):1404-7.
10. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Antin JH, etal., Blood. 1994 Aug 15;84(4):1342-8.
11. Interleukin-1 receptor antagonist gene polymorphism and mortality in patients with severe sepsis. Arnalich F, etal., Clin Exp Immunol. 2002 Feb;127(2):331-6.
12. Interleukin-1 receptor antagonist as a modulator of gender differences in the febrile response to lipopolysaccharide in rats. Ashdown H, etal., Am J Physiol Regul Integr Comp Physiol. 2007 Apr;292(4):R1667-74. Epub 2006 Nov 30.
13. Cytokine mRNA in the joints and draining lymph nodes of rats with adjuvant arthritis and effects of cyclosporin A. Ayer LM, etal., Inflammation. 2000 Oct;24(5):447-61.
14. Regulation of proinflammatory cytokines in seasonal allergic rhinitis. Bachert C, etal., Int Arch Allergy Immunol. 1999 Feb-Apr;118(2-4):375-9.
15. Multiplex immunoassay analysis of cytokines in idiopathic inflammatory myopathy. Baird GS and Montine TJ, Arch Pathol Lab Med. 2008 Feb;132(2):232-8. doi: 10.1043/1543-2165(2008)132[232:MIAOCI]2.0.CO;2.
16. The bisphosphonate alendronate improves the damage associated with trinitrobenzenesulfonic acid-induced colitis in rats. Ballester I, etal., Br J Pharmacol. 2007 May;151(2):206-15. Epub 2007 Mar 20.
17. Correlation of serum levels of interleukin-1 family members with disease activity and response to treatment in hairy cell leukemia. Barak V, etal., Eur Cytokine Netw. 1998 Mar;9(1):33-9.
18. Comparison of cytokine gene polymorphism in drug-induced maculopapular eruption, urticaria and drug reaction with eosinophilia and systemic symptoms (DRESS). Barbaud A, etal., J Eur Acad Dermatol Venereol. 2014 Apr;28(4):491-9. doi: 10.1111/jdv.12130. Epub 2013 Mar 6.
19. Intracisternal interleukin-1 receptor antagonist prevents postoperative cognitive decline and neuroinflammatory response in aged rats. Barrientos RM, etal., J Neurosci. 2012 Oct 17;32(42):14641-8. doi: 10.1523/JNEUROSCI.2173-12.2012.
20. Soluble interleukin-1 receptor antagonist concentration in patients with Graves' ophthalmopathy is neither related to cigarette smoking nor predictive of subsequent response to glucocorticoids. Bartalena L, etal., Clin Endocrinol (Oxf). 2000 May;52(5):647-51.
21. Interleukin-1 receptor antagonist as a biomarker for bronchiolitis obliterans syndrome in lung transplant recipients. Belperio JA, etal., Transplantation. 2002 Feb 27;73(4):591-9.
22. Blood serum interleukin-1 receptor antagonist in pars planitis and ocular Behcet disease. Benezra D, etal., Am J Ophthalmol. 1997 May;123(5):593-8.
23. Nucleotide variation, haplotype structure, and association with end-stage renal disease of the human interleukin-1 gene cluster. Bensen JT, etal., Genomics. 2003 Aug;82(2):194-217.
24. Altered levels of the soluble IL-1, IL-4 and TNF receptors, as well as the IL-1 receptor antagonist, in intermittent allergic rhinitis. Benson M, etal., Int Arch Allergy Immunol. 2004 Jul;134(3):227-32. Epub 2004 Jun 1.
25. Host adaptive immunity deficiency in severe pandemic influenza. Bermejo-Martin JF, etal., Crit Care. 2010 Sep 14;14(5):R167.
26. Attenuation of stroke size in rats using an adenoviral vector to induce overexpression of interleukin-1 receptor antagonist in brain. Betz AL, etal., J Cereb Blood Flow Metab. 1995 Jul;15(4):547-51.
27. Association of interleukin-1Ra gene polymorphism in patients with bladder cancer: case control study from North India. Bid HK, etal., Urology. 2006 May;67(5):1099-104.
28. Counteracting corneal immunoinflammatory lesion with interleukin-1 receptor antagonist protein. Biswas PS, etal., J Leukoc Biol. 2004 Oct;76(4):868-75. Epub 2004 Jul 16.
29. Interleukin-1 receptor antagonist allele (IL1RN*2) associated with nephropathy in diabetes mellitus. Blakemore AI, etal., Hum Genet. 1996 Mar;97(3):369-74.
30. Targeted systemic radiotherapy with scVEGF/177Lu leads to sustained disruption of the tumor vasculature and intratumoral apoptosis. Blankenberg FG, etal., J Nucl Med. 2011 Oct;52(10):1630-7. Epub 2011 Sep 2.
31. Acute bacterial inflammation of the mouse prostate. Boehm BJ, etal., Prostate. 2012 Feb;72(3):307-17. doi: 10.1002/pros.21433. Epub 2011 Jun 16.
32. Analysis of IL1 gene polymorphisms and transcript levels in periodontal and chronic kidney disease. Braosi AP, etal., Cytokine. 2012 Oct;60(1):76-82. Epub 2012 Jul 13.
33. Measurement of interleukin-1 receptor antagonist in patients with systemic lupus erythematosus could predict renal manifestation of the disease. Brugos B, etal., Hum Immunol. 2010 Sep;71(9):874-7. Epub 2010 Jun 9.
34. Interleukin 1 receptor antagonist (IL1RA) in acute leukaemia: IL1RA is both secreted spontaneously by myelogenous leukaemia blasts and is a part of the acute phase reaction in patients with chemotherapy-induced leucopenia. Bruserud O, etal., Eur J Haematol. 1996 Jul;57(1):87-95.
35. Evaluation of five interleukin genes for association with end-stage renal disease in white Europeans. Buckham TA, etal., Am J Nephrol. 2010;32(2):103-8. Epub 2010 Jun 16.
36. Energy-sensing factors coactivator peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha) and AMP-activated protein kinase control expression of inflammatory mediators in liver: induction of interleukin 1 receptor antagonist. Buler M, etal., J Biol Chem. 2012 Jan 13;287(3):1847-60. doi: 10.1074/jbc.M111.302356. Epub 2011 Nov 23.
37. Interleukin-1 receptor antagonist gene polymorphism affects the progression of chronic renal failure. Buraczynska M, etal., Cytokine. 2006 Nov;36(3-4):167-72. Epub 2007 Jan 16.
38. Association between bronchopulmonary dysplasia and MBL2 and IL1-RN polymorphisms. Cakmak BC, etal., Pediatr Int. 2012 Dec;54(6):863-8. doi: 10.1111/j.1442-200X.2012.03714.x. Epub 2012 Nov 21.
39. Trigeminal-Rostral Ventromedial Medulla circuitry is involved in orofacial hyperalgesia contralateral to tissue injury. Chai B, etal., Mol Pain. 2012 Oct 23;8:78. doi: 10.1186/1744-8069-8-78.
40. Delivery of biologically active anti-inflammatory cytokines IL-10 and IL-1ra in vivo by the Shigella type III secretion apparatus. Chamekh M, etal., J Immunol. 2008 Mar 15;180(6):4292-8.
41. Dual biological functions of an interleukin-1 receptor antagonist-interleukin-10 fusion protein and its suppressive effects on joint inflammation. Chang DM, etal., Immunology. 2004 Aug;112(4):643-50.
42. Interleukin-1 receptor antagonist modulates the progression of a spontaneously occurring IgA nephropathy in mice. Chen A, etal., Am J Kidney Dis. 1997 Nov;30(5):693-702.
43. Increased prevalence of interleukin-1 receptor antagonist gene polymorphism in patients with chronic rhinosinusitis. Cheng YK, etal., Arch Otolaryngol Head Neck Surg. 2006 Mar;132(3):285-90.
44. Involvement of microglial P2X7 receptors and downstream signaling pathways in long-term potentiation of spinal nociceptive responses. Chu YX, etal., Brain Behav Immun. 2010 Oct;24(7):1176-89. Epub 2010 Jun 8.
45. Interleukin 1 receptor antagonist gene polymorphism association with lichen sclerosus. Clay FE, etal., Hum Genet. 1994 Oct;94(4):407-10.
46. Evaluation of interleukin-1 receptor antagonist (IL-1RA) and tumor necrosis factor binding protein (TNF-BP) in a rodent abscess model of host resistance. Colagiovanni DB and Shopp GM, Immunopharmacol Immunotoxicol. 1996 Aug;18(3):397-419.
47. Distinct cytokine production by lung and blood neutrophils from children with cystic fibrosis. Corvol H, etal., Am J Physiol Lung Cell Mol Physiol. 2003 Jun;284(6):L997-1003. Epub 2003 Jan 24.
48. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-1 receptor antagonist. Cunha JM, etal., Br J Pharmacol. 2000 Jul;130(6):1418-24.
49. Topical interleukin 1 receptor antagonist promotes corneal transplant survival. Dana MR, etal., Transplantation. 1997 May 27;63(10):1501-7.
50. Clinical correlates of elevated serum concentrations of cytokines and autoantibodies in patients with spinal cord injury. Davies AL, etal., Arch Phys Med Rehabil. 2007 Nov;88(11):1384-93.
51. Beneficial response to anakinra and thalidomide in Schnitzler's syndrome. de Koning HD, etal., Ann Rheum Dis. 2006 Apr;65(4):542-4. Epub 2005 Aug 11.
52. Expression of multiple cytokines and IL-1RA in the uvea and retina during endotoxin-induced uveitis in the rat. de Vos AF, etal., Invest Ophthalmol Vis Sci. 1994 Oct;35(11):3873-83.
53. [Role of interleukin-1 receptor antagonist in protecting kidney from injury induced by asphyxia in neonatal rats]. Dong WB, etal., Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2005 Oct;17(10):623-5.
54. The association between mortality rates and decreased concentrations of interleukin-10 and interleukin-1 receptor antagonist in the lung fluids of patients with the adult respiratory distress syndrome. Donnelly SC, etal., Ann Intern Med. 1996 Aug 1;125(3):191-6.
55. Interleukin-1 receptor antagonist binds to the type II interleukin-1 receptor on B cells and neutrophils. Dripps DJ, etal., J Biol Chem. 1991 Oct 25;266(30):20311-5.
56. Neutrophil apoptosis, activation and anti-inflammatory cytokine response in granulocyte colony-stimulating factor-treated patients with community-acquired pneumonia. Droemann D, etal., Respiration. 2006;73(3):340-6. Epub 2005 Dec 12.
57. Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behcet's disease. Duzgun N, etal., Rheumatol Int. 2005 Jan;25(1):1-5. Epub 2003 Nov 5.
58. The role of interleukin-1ss in arthritic pain: Main involvement in thermal but not in mechanical hyperalgesia in rat antigen-induced arthritis. Ebbinghaus M, etal., Arthritis Rheum. 2012 Aug 29. doi: 10.1002/art.34675.
59. Interleukin 1 receptor antagonist is a member of the interleukin 1 gene family: evolution of a cytokine control mechanism. Eisenberg SP, etal., Proc Natl Acad Sci U S A 1991 Jun 15;88(12):5232-6.
60. Correlation of metalloproteinase-2 and -9 with proinflammatory cytokines interleukin-1b, interleukin-12 and the interleukin-1 receptor antagonist in patients with chronic uveitis. El-Shabrawi YG, etal., Curr Eye Res. 2000 Mar;20(3):211-4.
61. Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease. Enriquez-de-Salamanca A, etal., Mol Vis. 2010 May 19;16:862-73.
62. Kainic acid induced expression of interleukin-1 receptor antagonist mRNA in the rat brain. Eriksson C, etal., Brain Res Mol Brain Res. 1998 Jul 15;58(1-2):195-208.
63. Interleukin-1 mediates endothelin-1-induced fever and prostaglandin production in the preoptic area of rats. Fabricio AS, etal., Am J Physiol Regul Integr Comp Physiol. 2006 Jun;290(6):R1515-23. Epub 2006 Feb 2.
64. Effects of aging and cytokine blockade on inflammatory cachexia. Fathalla B, etal., Clin Exp Rheumatol. 2004 Jan-Feb;22(1):85-90.
65. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. Fisher CJ Jr, etal., JAMA. 1994 Jun 15;271(23):1836-43.
66. Influence of pregnancy on plasma cytokines and the febrile response to intraperitoneal administration of bacterial endotoxin in rats. Fofie AE and Fewell JE, Exp Physiol. 2003 Nov;88(6):747-54.
67. Protection from experimental ventilator-induced acute lung injury by IL-1 receptor blockade. Frank JA, etal., Thorax. 2008 Feb;63(2):147-53. Epub 2007 Sep 27.
68. Interleukin-1-dependent sequential chemokine expression and inflammatory cell infiltration in ischemia-reperfusion injury. Furuichi K, etal., Crit Care Med. 2006 Sep;34(9):2447-55.
69. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
70. Serum IL-6 and IL-1-ra with sequential organ failure assessment scores in septic patients receiving high-volume haemofiltration and continuous venovenous haemofiltration. Ghani RA, etal., Nephrology (Carlton). 2006 Oct;11(5):386-93.
71. Association of the interleukin-1 receptor antagonist gene with asthma. Gohlke H, etal., Am J Respir Crit Care Med. 2004 Jun 1;169(11):1217-23. Epub 2004 Mar 12.
72. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. Goldbach-Mansky R, etal., N Engl J Med. 2006 Aug 10;355(6):581-92.
73. Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. Goodman RB, etal., Am J Respir Crit Care Med. 1996 Sep;154(3 Pt 1):602-11.
74. Lentiviral-mediated gene delivery to synovium: potent intra-articular expression with amplification by inflammation. Gouze E, etal., Mol Ther. 2003 Apr;7(4):460-6.
75. Murine monoclonal anti-tNF antibody administration has a beneficial effect on inflammatory bowel disease that develops in IL-10 knockout mice. Gratz R, etal., Dig Dis Sci. 2002 Aug;47(8):1723-7.
76. Rapid brain penetration of interleukin-1 receptor antagonist in rat cerebral ischaemia: pharmacokinetics, distribution, protection. Greenhalgh AD, etal., Br J Pharmacol. 2010 May;160(1):153-9. doi: 10.1111/j.1476-5381.2010.00684.x.
77. Interleukin-1 receptor antagonist is beneficial after subarachnoid haemorrhage in rat by blocking haem-driven inflammatory pathology. Greenhalgh AD, etal., Dis Model Mech. 2012 Nov;5(6):823-33. doi: 10.1242/dmm.008557. Epub 2012 May 31.
78. Impact of an interleukin-1 receptor antagonist and erythropoietin on experimental myocardial ischemia/reperfusion injury. Grothusen C, etal., ScientificWorldJournal. 2012;2012:737585. Epub 2012 May 2.
79. Association between Albuminuria, Kidney Function, and Inflammatory Biomarker Profile. Gupta J, etal., Clin J Am Soc Nephrol. 2012 Sep 27.
80. Interleukin-1 cluster gene polymorphisms in childhood IgA nephropathy. Hahn WH, etal., Pediatr Nephrol. 2009 Jul;24(7):1329-36. Epub 2009 Mar 12.
81. Role of IL-1 in renal ischemic reperfusion injury. Haq M, etal., J Am Soc Nephrol. 1998 Apr;9(4):614-9.
82. Transfer of the interleukin-1 receptor antagonist gene into rat liver abrogates hepatic ischemia-reperfusion injury. Harada H, etal., Transplantation. 2002 Nov 27;74(10):1434-41.
83. Substance P in polymicrobial sepsis: molecular fingerprint of lung injury in preprotachykinin-A-/- mice. Hegde A, etal., Mol Med. 2010 May-Jun;16(5-6):188-98. Epub 2010 Feb 8.
84. Causal links between brain cytokines and experimental febrile convulsions in the rat. Heida JG and Pittman QJ, Epilepsia. 2005 Dec;46(12):1906-13.
85. The influence of uremic serum on interleukin-1beta and interleukin-1 receptor antagonist production by peripheral blood mononuclear cells. Higuchi T, etal., Ther Apher Dial. 2006 Feb;10(1):65-71.
86. Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. Hirsch E, etal., Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):11008-13.
87. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. Horai R, etal., J Exp Med. 2000 Jan 17;191(2):313-20.
88. Lack of associations between several polymorphisms in cytokine genes and the risk of chronic obstructive pulmonary diseases in Taiwan. Hsieh MH, etal., Kaohsiung J Med Sci. 2008 Mar;24(3):126-37.
89. Interleukin-1 receptor antagonist enhances islet engraftment without impacting serum levels of nitrite or osteopontin. Hsu BR, etal., Transplant Proc. 2009 Jun;41(5):1781-5.
90. Interleukin-1 beta, interleukin-1 receptor antagonist and interleukin-6 plasma levels and cytokine gene polymorphisms in chronic lymphocytic leukemia: correlation with prognostic parameters. Hulkkonen J, etal., Haematologica. 2000 Jun;85(6):600-6.
91. Regulation of brain interleukin-1 beta (IL-1 beta) system mRNAs in response to pathophysiological concentrations of IL-1 beta in the cerebrospinal fluid. Ilyin SE, etal., J Mol Neurosci. 1996 Fall;7(3):169-81.
92. Effects of interleukin-1 receptor antagonist overexpression on infection by Listeria monocytogenes. Irikura VM, etal., Infect Immun. 1999 Apr;67(4):1901-9.
93. The mechanism of altered neural function in a rat model of acute colitis. Jacobson K, etal., Gastroenterology. 1997 Jan;112(1):156-62.
94. Enhanced production of IL-1 receptor antagonist by alveolar macrophages from patients with interstitial lung disease. Janson RW, etal., Am Rev Respir Dis. 1993 Aug;148(2):495-503.
95. Acute bile duct ligation ameliorates ischemic renal failure. Jeyarajah DR, etal., Nephron Physiol. 2003;95(2):p28-35.
96. Allergic rhinitis and polymorphisms of the interleukin 1 gene complex. Joki-Erkkila VP, etal., Ann Allergy Asthma Immunol. 2003 Sep;91(3):275-9.
97. Association between SLE nephritis and polymorphic variants of the CRP and FcgammaRIIIa genes. Jonsen A, etal., Rheumatology (Oxford). 2007 Sep;46(9):1417-21. Epub 2007 Jun 27.
98. Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Juge-Aubry CE, etal., Diabetes. 2003 May;52(5):1104-10.
99. Significance of IL-1beta and IL-1 receptor antagonist (IL-1Ra) in bronchoalveolar lavage fluid (BALF) in patients with diffuse panbronchiolitis (DPB). Kadota J, etal., Clin Exp Immunol. 1996 Mar;103(3):461-6.
100. Contribution of IL-1 to resistance to Streptococcus pneumoniae infection. Kafka D, etal., Int Immunol. 2008 Sep;20(9):1139-46. Epub 2008 Jul 1.
101. Interleukin-1 balance in the lungs of preterm infants who develop bronchopulmonary dysplasia. Kakkera DK, etal., Biol Neonate. 2005;87(2):82-90. Epub 2004 Oct 14.
102. Prevention of allergic eye disease by treatment with IL-1 receptor antagonist. Keane-Myers AM, etal., Invest Ophthalmol Vis Sci. 1999 Nov;40(12):3041-6.
103. Early cytokine and chemokine gene expression during Pseudomonas aeruginosa corneal infection in mice. Kernacki KA, etal., Infect Immun. 1998 Jan;66(1):376-9.
104. Graves' ophthalmopathy and gene polymorphisms in interleukin-1alpha, interleukin-1beta, interleukin-1 receptor and interleukin-1 receptor antagonist. Khalilzadeh O, etal., Clin Experiment Ophthalmol. 2009 Aug;37(6):614-9. doi: 10.1111/j.1442-9071.2009.02093.x.
105. Association of IL-1beta, IL-1ra, and TNF-alpha gene polymorphisms in childhood nephrotic syndrome. Kim SD, etal., Pediatr Nephrol. 2004 Mar;19(3):295-9. Epub 2004 Feb 3.
106. Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. Kimble RB, etal., J Clin Invest. 1994 May;93(5):1959-67.
107. Quantitative and qualitative urinary cellular patterns correlate with progression of murine glomerulonephritis. Kimura J, etal., PLoS One. 2011 Jan 31;6(1):e16472.
108. Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial. Klatte T, etal., Br J Cancer. 2006 Nov 6;95(9):1167-73. Epub 2006 Oct 10.
109. Relative release of interleukin-1 beta and interleukin-1 receptor antagonist by alveolar macrophages. A study in asbestos-induced lung disease, sarcoidosis, and idiopathic pulmonary fibrosis. Kline JN, etal., Chest. 1993 Jul;104(1):47-53.
110. Serum levels of tumor necrosis factor-alpha, soluble intercellular adhesion molecule-1, soluble vascular cell adhesion molecule-1, and soluble interleukin-1 receptor antagonist in patients with thyroid eye disease undergoing treatment with somatostatin analogues. Krassas GE, etal., Thyroid. 2001 Dec;11(12):1115-22.
111. Cytokines in sputum and serum from patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection as markers of destructive inflammation in the lungs. Kronborg G, etal., Pediatr Pulmonol. 1993 May;15(5):292-7.
112. NLRP3 E311K mutation in a large family with Muckle-Wells syndrome--description of a heterogeneous phenotype and response to treatment. Kuemmerle-Deschner JB, etal., Arthritis Res Ther. 2011;13(6):R196. Epub 2011 Dec 6.
113. Interleukin 1 components in cicatricial pemphigoid. Role in intravenous immunoglobulin therapy. Kumari S, etal., Cytokine. 2001 May 21;14(4):218-24.
114. Interleukin-1 receptor antagonist halts the progression of established crescentic glomerulonephritis in the rat. Lan HY, etal., Kidney Int. 1995 May;47(5):1303-9.
115. Attenuated mRNA expression of inflammatory mediators in neonatal rat lung following lipopolysaccharide treatment. Le Rouzic V, etal., J Inflamm Res. 2012;5:99-109. doi: 10.2147/JIR.S33737. Epub 2012 Sep 7.
116. Changes of plasma interleukin-1 receptor antagonist, interleukin-8 and other serologic markers during chemotherapy in patients with active pulmonary tuberculosis. Lee JH and Chang JH, Korean J Intern Med. 2003 Sep;18(3):138-45.
117. Polymorphisms in interleukin-1B and its receptor antagonist genes and the risk of chronic obstructive pulmonary disease in a Korean population: a case-control study. Lee JM, etal., Respir Med. 2008 Sep;102(9):1311-20. Epub 2008 Jun 24.
118. Genetics of diabetic nephropathy in type 2 DM: candidate gene analysis for the pathogenic role of inflammation. Lee SH, etal., Nephrology (Carlton). 2005 Oct;10 Suppl:S32-6.
119. [Effects of interleukin-10 on expression of inflammatory mediators and anti-inflammatory mediators during acute lung injury in rats] Li HX, etal., Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2005 Jun;17(6):338-41.
120. Suppression of immune-mediated ocular inflammation in mice by interleukin 1 receptor antagonist administration. Lim WK, etal., Arch Ophthalmol. 2005 Jul;123(7):957-63.
121. Association analysis of polymorphisms at the interleukin-1 locus in essential hypertension. Lin RC and Morris BJ, Am J Med Genet. 2002 Feb 1;107(4):311-6.
122. Interleukin 1 receptor antagonist gene polymorphism and risk of lung cancer: a possible interaction with polymorphisms in the interleukin 1 beta gene. Lind H, etal., Lung Cancer. 2005 Dec;50(3):285-90. Epub 2005 Aug 26.
123. Circulating inflammatory cytokine levels in hemolytic uremic syndrome. Litalien C, etal., Pediatr Nephrol. 1999 Nov;13(9):840-5.
124. Effect of hydrodynamics-based gene delivery of plasmid DNA encoding interleukin-1 receptor antagonist-Ig for treatment of rat autoimmune myocarditis: possible mechanism for lymphocytes and noncardiac cells. Liu H, etal., Circulation. 2005 Apr 5;111(13):1593-600. Epub 2005 Mar 28.
125. Selective delivery of interleukine-1 receptor antagonist to inflamed joint by albumin fusion. Liu M, etal., BMC Biotechnol. 2012 Sep 25;12(1):68.
126. Interleukin-1 receptor antagonist allele: is it a genetic link between Henoch-Schonlein nephritis and IgA nephropathy? Liu ZH, etal., Kidney Int. 1997 Jun;51(6):1938-42.
127. Age-Related Comparisons of Evolution of the Inflammatory Response After Intracerebral Hemorrhage in Rats. Lively S and Schlichter LC, Transl Stroke Res. 2012 Jul;3(Suppl 1):132-146. Epub 2012 Mar 16.
128. Interleukin-1 receptor antagonist exerts agonist activity in the hippocampus independent of the interleukin-1 type I receptor. Loscher CE, etal., J Neuroimmunol. 2003 Apr;137(1-2):117-24.
129. Associations between interleukin-1 (IL-1) gene variations or IL-1 receptor antagonist levels and the development of type 2 diabetes. Luotola K, etal., J Intern Med. 2011 Mar;269(3):322-32. doi: 10.1111/j.1365-2796.2010.02294.x.
130. The immune-inflammatory pathophysiology of fibromyalgia: increased serum soluble gp130, the common signal transducer protein of various neurotrophic cytokines. Maes M, etal., Psychoneuroendocrinology. 1999 May;24(4):371-83.
131. Proinflammatory cytokine gene polymorphisms among Iranian patients with asthma. Mahdaviani SA, etal., J Clin Immunol. 2009 Jan;29(1):57-62. Epub 2008 Sep 2.
132. Interleukin-1beta and receptor antagonist (IL-1Ra) gene polymorphisms and the prediction of the risk of end-stage renal disease. Manchanda PK, etal., Biomarkers. 2006 Mar-Apr;11(2):164-73.
133. Copper chelation represses the vascular response to injury. Mandinov L, etal., Proc Natl Acad Sci U S A. 2003 May 27;100(11):6700-5. Epub 2003 May 16.
134. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Mansfield JC, etal., Gastroenterology. 1994 Mar;106(3):637-42.
135. Effects of coupled plasma filtration adsorption on immune function of patients with multiple organ dysfunction syndrome. Mao HJ, etal., Int J Artif Organs. 2009 Jan;32(1):31-8.
136. Imbalance production between interleukin-1beta (IL-1beta) and IL-1 receptor antagonist (IL-1Ra) in bronchial asthma. Mao XQ, etal., Biochem Biophys Res Commun. 2000 Sep 24;276(2):607-12.
137. Protective effect of the interleukin-1 receptor antagonist (IL-1ra) on experimental allergic encephalomyelitis in rats. Martin D and Near SL, J Neuroimmunol. 1995 Sep;61(2):241-5.
138. Overexpression of interleukin-1 receptor antagonist reduces brain edema induced by intracerebral hemorrhage and thrombin. Masada T, etal., Acta Neurochir Suppl. 2003;86:463-7.
139. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Mathai SK, etal., Lab Invest. 2010 Jun;90(6):812-23. Epub 2010 Apr 19.
140. IL-1 plays an important role in lipid metabolism by regulating insulin levels under physiological conditions. Matsuki T, etal., J Exp Med. 2003 Sep 15;198(6):877-88.
141. Noradrenaline induces IL-1ra and IL-1 type II receptor expression in primary glial cells and protects against IL-1beta-induced neurotoxicity. McNamee EN, etal., Eur J Pharmacol. 2010 Jan 25;626(2-3):219-28. doi: 10.1016/j.ejphar.2009.09.054. Epub 2009 Oct 8.
142. IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin? Meier CA, etal., J Clin Endocrinol Metab. 2002 Mar;87(3):1184-8.
143. Cytokine gene polymorphisms involved in chronicity and complications of anterior uveitis. Menezo V, etal., Cytokine. 2006 Aug;35(3-4):200-6. Epub 2006 Sep 26.
144. Cytokine profile in autosomal dominant polycystic kidney disease. Merta M, etal., Biochem Mol Biol Int. 1997 Mar;41(3):619-24.
145. Anakinra for rheumatoid arthritis: a systematic review. Mertens M and Singh JA, J Rheumatol. 2009 Jun;36(6):1118-25. Epub 2009 May 15.
146. Effect of treatment with interleukin-1 receptor antagonist on the development of carrageenan-induced pleurisy in the rat. Meyers KP, etal., Inflammation. 1993 Apr;17(2):121-34.
147. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
148. Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. Milligan ED, etal., J Neurosci. 2003 Feb 1;23(3):1026-40.
149. Genotype and haplotype determination of IL1B (g. -511C>T and g. +3954C>T) and (IL1RN) in pediatric nephrolithiasis. Mittal RD, etal., Clin Chim Acta. 2007 Apr;379(1-2):42-7. Epub 2006 Dec 15.
150. Association of interleukin-1beta gene and receptor antagonist polymorphisms with calcium oxalate urolithiasis. Mittal RD, etal., J Endourol. 2007 Dec;21(12):1565-70.
151. The inflammatory milieu associated with conjunctivalized cornea and its alteration with IL-1 RA gene therapy. Moore JE, etal., Invest Ophthalmol Vis Sci. 2002 Sep;43(9):2905-15.
152. Pilot study on the effects of high cutoff hemofiltration on the need for norepinephrine in septic patients with acute renal failure. Morgera S, etal., Crit Care Med. 2006 Aug;34(8):2099-104.
153. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism. Moulin D, etal., Arthritis Rheum. 2005 Mar;52(3):759-69.
154. IL-1 is required for allergen-specific Th2 cell activation and the development of airway hypersensitivity response. Nakae S, etal., Int Immunol. 2003 Apr;15(4):483-90.
155. Plasma exchange therapy for the treatment of Escherichia coli O-157 associated hemolytic uremic syndrome. Nakatani T, etal., Int J Mol Med. 2002 Nov;10(5):585-8.
156. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
157. Interleukin 1 beta, tumour necrosis factor-alpha and interleukin 1 receptor antagonist in newly diagnosed insulin-dependent diabetes mellitus: comparison to long-standing diabetes and healthy individuals. Netea MG, etal., Cytokine. 1997 Apr;9(4):284-7.
158. Decreased mortality of severe acute pancreatitis after proximal cytokine blockade. Norman JG, etal., Ann Surg. 1995 Jun;221(6):625-31; discussion 631-4.
159. Substitution at IL1RN and deletion at SLC4A11 segregating with phenotype in familial keratoconus. Nowak DM, etal., Invest Ophthalmol Vis Sci. 2013 Mar 1;54(3):2207-15. doi: 10.1167/iovs.13-11592.
160. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
161. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Ortiz LA, etal., Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):11002-7. Epub 2007 Jun 14.
162. Distinct sputum cytokine profiles in cystic fibrosis and other chronic inflammatory airway disease. Osika E, etal., Eur Respir J. 1999 Aug;14(2):339-46.
163. Interleukin-1beta mediates the memory impairment associated with a delayed type hypersensitivity response to bacillus Calmette-Guerin in the rat hippocampus. Palin K, etal., Brain Behav Immun. 2004 May;18(3):223-30.
164. Influence of the course of brain inflammation on the endogenous IL-1beta/IL-1Ra balance in the model of brain delayed-type hypersensitivity response to bacillus Calmette-Guerin in Lewis rats. Palin K, etal., J Neuroimmunol. 2004 Apr;149(1-2):22-30.
165. Ibuprofen protects ischemia-induced neuronal injury via up-regulating interleukin-1 receptor antagonist expression. Park EM, etal., Neuroscience. 2005;132(3):625-31.
166. Interleukin-1 receptor antagonist attenuates airway hyperresponsiveness following exposure to ozone. Park JW, etal., Am J Respir Cell Mol Biol. 2004 Jun;30(6):830-6. Epub 2004 Jan 30.
167. Release of anti-inflammatory mediators after major torso trauma correlates with the development of postinjury multiple organ failure. Partrick DA, etal., Am J Surg. 1999 Dec;178(6):564-9.
168. Association between interleukin-1 receptor antagonist gene and asthma-related traits in a German adult population. Pattaro C, etal., Allergy. 2006 Feb;61(2):239-44.
169. Interleukin-1 receptor antagonist intron 2 variable number of tandem repeats polymorphism and respiratory failure in children with community-acquired pneumonia. Patwari PP, etal., Pediatr Crit Care Med. 2008 Nov;9(6):553-9.
170. Effect of acute hyperglycaemia on selected plasma and urinary cytokine antagonists in Type 1 diabetes mellitus. Pelikanova T, etal., Diabetologia. 2003 Apr;46(4):470-4. Epub 2003 Apr 5.
171. IL-1 receptor antagonist (IL-1RA) gene polymorphism in Sjogren's syndrome and rheumatoid arthritis. Perrier S, etal., Clin Immunol Immunopathol. 1998 Jun;87(3):309-13.
172. Differences in the genotypes and plasma concentrations of the INTERLEUKIN-1 receptor antagonist in black and white South African asthmatics and control subjects. Pillay V, etal., Cytokine. 2000 Jun;12(6):819-21.
173. Interleukin-1 accounts for intrarenal Th17 cell activation during ureteral obstruction. Pindjakova J, etal., Kidney Int. 2012 Feb;81(4):379-90. doi: 10.1038/ki.2011.348. Epub 2011 Oct 5.
174. Interleukin-1beta causes fluoxetine resistance in an animal model of epilepsy-associated depression. Pineda EA, etal., Neurotherapeutics. 2012 Apr;9(2):477-85.
175. PID Annotation Import Pipeline Pipeline to import Pathway Interaction Database annotations from NCI into RGD
176. Impact of IL-1 signalling on experimental uveitis and arthritis. Planck SR, etal., Ann Rheum Dis. 2012 May;71(5):753-60. doi: 10.1136/annrheumdis-2011-200556. Epub 2012 Jan 20.
177. Brain cytokine mRNAs in anorectic rats bearing prostate adenocarcinoma tumor cells. Plata-Salaman CR, etal., Am J Physiol. 1998 Aug;275(2 Pt 2):R566-73.
178. Mucosal delivery of anti-inflammatory IL-1Ra by sporulating recombinant bacteria. Porzio S, etal., BMC Biotechnol. 2004 Oct 30;4:27.
179. Delayed administration of interleukin-1 receptor antagonist reduces ischemic brain damage and inflammation in comorbid rats. Pradillo JM, etal., J Cereb Blood Flow Metab. 2012 Sep;32(9):1810-9. doi: 10.1038/jcbfm.2012.101. Epub 2012 Jul 11.
180. Duration and severity of symptoms and levels of plasma interleukin-1 receptor antagonist, soluble tumor necrosis factor receptor, and adhesion molecules in patients with common cold treated with zinc acetate. Prasad AS, etal., J Infect Dis. 2008 Mar 15;197(6):795-802.
181. Inflammatory mediators in Escherichia coli O157:H7 hemorrhagic colitis and hemolytic-uremic syndrome. Proulx F, etal., Pediatr Infect Dis J. 1998 Oct;17(10):899-904.
182. Human immunodeficiency virus-1 coat protein gp120 impairs contextual fear conditioning: a potential role in AIDS related learning and memory impairments. Pugh CR, etal., Brain Res. 2000 Apr 7;861(1):8-15.
183. Interleukin-1R antagonist gene and pre-natal smoke exposure are associated with childhood asthma. Ramadas RA, etal., Eur Respir J. 2007 Mar;29(3):502-8. Epub 2006 Nov 15.
184. GOA pipeline RGD automated data pipeline
185. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
186. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
187. IL1RN VNTR and IL2-330 polymorphic genes are independently associated with chronic immune thrombocytopenia. Rocha AM, etal., Br J Haematol. 2010 Sep;150(6):679-84. doi: 10.1111/j.1365-2141.2010.08318.x.
188. Interleukin-1 receptor antagonist expression in sarcoidosis. Rolfe MW, etal., Am Rev Respir Dis. 1993 Nov;148(5):1378-84.
189. Imbalances in serum proinflammatory cytokines and their soluble receptors: a putative role in the progression of idiopathic IgA nephropathy (IgAN) and Henoch-Schonlein purpura nephritis, and a potential target of immunoglobulin therapy? Rostoker G, etal., Clin Exp Immunol. 1998 Dec;114(3):468-76.
190. Administration of interleukin-1 receptor antagonist ameliorates renal ischemia-reperfusion injury. Rusai K, etal., Transpl Int. 2008 Jun;21(6):572-80. Epub 2008 Mar 18.
191. Interleukin-1 receptor antagonist prevents low dose streptozotocin induced diabetes in mice. Sandberg JO, etal., Biochem Biophys Res Commun. 1994 Jul 15;202(1):543-8.
192. IL-1 receptor antagonist inhibits recurrence of disease after syngeneic pancreatic islet transplantation to spontaneously diabetic non-obese diabetic (NOD) mice. Sandberg JO, etal., Clin Exp Immunol. 1997 May;108(2):314-7.
193. Imbalances between interleukin-1 and tumor necrosis factor agonists and antagonists in stable COPD. Sapey E, etal., J Clin Immunol. 2009 Jul;29(4):508-16. Epub 2009 Mar 17.
194. Unmasking of LPA1 receptor-mediated migration response to lysophosphatidic acid by interleukin-1beta-induced attenuation of Rho signaling pathways in rat astrocytes. Sato K, etal., J Neurochem. 2011 Apr;117(1):164-74. doi: 10.1111/j.1471-4159.2011.07188.x. Epub 2011 Feb 9.
195. Neutrophil serine proteases promote IL-1beta generation and injury in necrotizing crescentic glomerulonephritis. Schreiber A, etal., J Am Soc Nephrol. 2012 Mar;23(3):470-82. Epub 2012 Jan 12.
196. Association of interleukin-1beta and interleukin-1 receptor antagonist genes with disease severity in MS. Schrijver HM, etal., Neurology 1999 Feb;52(3):595-9.
197. Regulatory effects of endogenous interleukin-1 receptor antagonist protein in immunoglobulin G immune complex-induced lung injury. Shanley TP, etal., J Clin Invest. 1996 Feb 15;97(4):963-70.
198. Interleukin 1 receptor blockade reduces tumor necrosis factor production, tissue injury, and mortality after hepatic ischemia-reperfusion in the rat. Shito M, etal., Transplantation. 1997 Jan 15;63(1):143-8.
199. Impact of interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphism on IgA nephropathy. Shu KH, etal., Kidney Int. 2000 Aug;58(2):783-9.
200. Genetic susceptibility to respiratory syncytial virus bronchiolitis in preterm children is associated with airway remodeling genes and innate immune genes. Siezen CL, etal., Pediatr Infect Dis J. 2009 Apr;28(4):333-5.
201. The IL-1 family: regulators of immunity. Sims JE and Smith DE, Nat Rev Immunol. 2010 Feb;10(2):89-102. Epub 2010 Jan 18.
202. Production of interleukin-10 by human bronchogenic carcinoma. Smith DR, etal., Am J Pathol. 1994 Jul;145(1):18-25.
203. Increased interleukin-1 receptor antagonist in idiopathic pulmonary fibrosis. A compartmental analysis. Smith DR, etal., Am J Respir Crit Care Med. 1995 Jun;151(6):1965-73.
204. Genetic variability in the severity and outcome of community-acquired pneumonia. Sole-Violan J, etal., Respir Med. 2010 Mar;104(3):440-7. Epub 2009 Nov 8.
205. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Solomon A, etal., Invest Ophthalmol Vis Sci. 2001 Sep;42(10):2283-92.
206. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Strausberg RL, etal., Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16899-903. Epub 2002 Dec 11.
207. The role of cytokines in the behavioral responses to endotoxin and influenza virus infection in mice: effects of acute and chronic administration of the interleukin-1-receptor antagonist (IL-1ra). Swiergiel AH, etal., Brain Res. 1997 Nov 21;776(1-2):96-104.
208. Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. Szarka A, etal., BMC Immunol. 2010 Dec 2;11:59.
209. Interleukin-1 receptor antagonist modifies the changes in vital organs induced by acute necrotizing pancreatitis in a rat experimental model. Tanaka N, etal., Crit Care Med. 1995 May;23(5):901-8.
210. Severity of alopecia areata is associated with a polymorphism in the interleukin-1 receptor antagonist gene. Tarlow JK, etal., J Invest Dermatol. 1994 Sep;103(3):387-90.
211. Adenoviral overproduction of interleukin-1 receptor antagonist increases beta cell replication and mass in syngeneically transplanted islets, and improves metabolic outcome. Tellez N, etal., Diabetologia. 2007 Mar;50(3):602-11. Epub 2007 Jan 13.
212. Tobacco smoking associated with the increases of the bronchoalveolar levels of interleukin-5 and interleukin-1 receptor antagonist in acute eosinophilic pneumonia. Teng Y and Gao Y, Eur Rev Med Pharmacol Sci. 2014;18(6):887-93.
213. The detrimental effects of IFN-alpha on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. Thacker SG, etal., J Immunol. 2010 Oct 1;185(7):4457-69. Epub 2010 Aug 30.
214. Balance of pro- and anti-inflammatory cytokines correlates with outcome of acute experimental Pseudomonas aeruginosa keratitis. Thakur A, etal., Infect Immun. 2002 Apr;70(4):2187-97.
215. Evolution of gene expression changes in newborn rats after mechanical ventilation with reversible intubation. Trummer-Menzi E, etal., Pediatr Pulmonol. 2012 Jul 10. doi: 10.1002/ppul.22613.
216. The different expression patterns of interleukin-1 receptor antagonist in systemic lupus erythematosus. Tsai LJ, etal., Tissue Antigens. 2006 Dec;68(6):493-501.
217. Suppression of experimental uveitis by a recombinant adeno-associated virus vector encoding interleukin-1 receptor antagonist. Tsai ML, etal., Mol Vis. 2009 Aug 8;15:1542-52.
218. Imbalances between tumor necrosis factor-alpha and its soluble receptor forms, and interleukin-1beta and interleukin-1 receptor antagonist in BAL fluid of cavitary pulmonary tuberculosis. Tsao TC, etal., Chest. 2000 Jan;117(1):103-9.
219. Soluble TNF-alpha receptor and IL-1 receptor antagonist elevation in BAL in active pulmonary TB. Tsao TC, etal., Eur Respir J. 1999 Sep;14(3):490-5.
220. Interleukin-1 alpha and interleukin-1 receptor antagonist in the urine of children with acute pyelonephritis and relation to renal scarring. Tullus K, etal., Acta Paediatr. 1996 Feb;85(2):158-62.
221. Endotoxin-induced cytokine gene expression in vivo. IV. Expression of interleukin-1 alpha/beta and interleukin-1 receptor antagonist mRNA during endotoxemia and during endotoxin-initiated local acute inflammation. Ulich TR, etal., Am J Pathol. 1992 Jul;141(1):61-8.
222. Haplotypes of IL1B, IL1RN, IL1R1, and IL1R2 and the risk of venous thrombosis. van Minkelen R, etal., Arterioscler Thromb Vasc Biol. 2007 Jun;27(6):1486-91. Epub 2007 Apr 5.
223. Cytokine gene polymorphisms and high-resolution-computed tomography score in idiopathic pulmonary fibrosis. Vasakova M, etal., Respir Med. 2007 May;101(5):944-50. Epub 2006 Oct 23.
224. Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases. Vidal-Vanaclocha F, etal., Cancer Res. 1994 May 15;54(10):2667-72.
225. Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease. Vijmasi T, etal., Mol Vis. 2013 Sep 19;19:1957-65. eCollection 2013.
226. Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline. Voelkel NF, etal., Am J Respir Cell Mol Biol. 1994 Dec;11(6):664-75.
227. Adenovirus expressing interleukin-1 receptor antagonist alleviates allergic airway inflammation in a murine model of asthma. Wang CC, etal., Gene Ther. 2006 Oct;13(19):1414-21. Epub 2006 May 25.
228. Interleukin-1 beta induction of neuron apoptosis depends on p38 mitogen-activated protein kinase activity after spinal cord injury. Wang XJ, etal., Acta Pharmacol Sin. 2005 Aug;26(8):934-42.
229. Association of interleukin-1 receptor antagonist gene polymorphism with IgA nephropathy. Watanabe M, etal., Nephron. 2002 Aug;91(4):744-6.
230. Altered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates. Wetzler M, etal., Blood. 1994 Nov 1;84(9):3142-7.
231. Induction of pituitary cytokine transcripts by peripheral lipopolysaccharide. Whiteside MB, etal., J Neuroendocrinol. 1999 Feb;11(2):115-20.
232. Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphisms. Whyte M, etal., Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):755-8.
233. Influence of polymorphism in the genes for the interleukin (IL)-1 receptor antagonist and IL-1beta on tuberculosis. Wilkinson RJ, etal., J Exp Med. 1999 Jun 21;189(12):1863-74.
234. Genetically modified bone marrow-derived vehicle cells site specifically deliver an anti-inflammatory cytokine to inflamed interstitium of obstructive nephropathy. Yamagishi H, etal., J Immunol. 2001 Jan 1;166(1):609-16.
235. Mesenchymal Stem Cell: Does it Work in an Experimental Model with Acute Respiratory Distress Syndrome? Yilmaz S, etal., Stem Cell Rev. 2012 Jul 19.
236. Prophylaxis of antibody-induced acute glomerulonephritis with genetically modified bone marrow-derived vehicle cells. Yokoo T, etal., Hum Gene Ther. 1999 Nov 1;10(16):2673-8.
237. Rhinovirus regulation of IL-1 receptor antagonist in vivo and in vitro: a potential mechanism of symptom resolution. Yoon HJ, etal., J Immunol. 1999 Jun 15;162(12):7461-9.
238. IL-1 up-regulates osteopontin expression in experimental crescentic glomerulonephritis in the rat. Yu XQ, etal., Am J Pathol. 1999 Mar;154(3):833-41.
239. The experimental treatment of corneal graft rejection with the interleukin-1 receptor antagonist (IL-1ra) gene. Yuan J, etal., PLoS One. 2013 May 28;8(5):e60714. doi: 10.1371/journal.pone.0060714. Print 2013.
240. Association of tumor necrosis factor-alpha and interleukin-1 gene polymorphisms with silicosis. Yucesoy B, etal., Toxicol Appl Pharmacol. 2001 Apr 1;172(1):75-82.
241. Interleukin-1 receptor antagonist gene polymorphism increases susceptibility to septic shock in children with acute lymphoblastic leukemia. Zapata-Tarres M, etal., Pediatr Infect Dis J. 2013 Feb;32(2):136-9. doi: 10.1097/INF.0b013e31827566dd.
242. Association of interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms in Turkish children with atopic asthma. Zeyrek D, etal., Allergy Asthma Proc. 2008 Sep-Oct;29(5):468-74.
243. Electroacupuncture attenuates bone cancer pain and inhibits spinal interleukin-1 beta expression in a rat model. Zhang RX, etal., Anesth Analg. 2007 Nov;105(5):1482-8, table of contents.
244. Therapeutic effect of exogenous bone marrowderived mesenchymal stem cell transplantation on silicosis via paracrine mechanisms in rats. Zhao MM, etal., Mol Med Rep. 2013 Sep;8(3):741-6. doi: 10.3892/mmr.2013.1580. Epub 2013 Jul 10.
245. Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Zheng C, etal., Br J Haematol. 2000 Apr;109(1):39-45.
246. Amniotic-fluid-derived mesenchymal stem cells overexpressing interleukin-1 receptor antagonist improve fulminant hepatic failure. Zheng YB, etal., PLoS One. 2012;7(7):e41392. Epub 2012 Jul 23.
247. Expression of cell adhesion molecules on limbal and neovascular endothelium in corneal inflammatory neovascularization. Zhu SN and Dana MR, Invest Ophthalmol Vis Sci. 1999 Jun;40(7):1427-34.
248. Roles of central interleukin-1 on stress-induced-hypertension and footshock-induced-analgesia in rats. Zou CJ, etal., Neurosci Lett. 2001 Sep 21;311(1):41-4.
249. [Prognostic values of serum concentration and urinary excretion of interleukin-1 receptor antagonist and tumor necrosis factor receptors type I and II in patients with IGA nephropathy]. Zwiech R, etal., Pol Arch Med Wewn. 2005 Apr;113(4):326-33.
Additional References at PubMed
PMID:1828071   PMID:1830582   PMID:2137200   PMID:2139180   PMID:9185517   PMID:10443688   PMID:11515103   PMID:12483741   PMID:12858036   PMID:15240711   PMID:15489334   PMID:15932594  
PMID:18299269   PMID:18455872   PMID:18511291   PMID:19056867   PMID:19742300   PMID:22827713   PMID:23376485   PMID:23747799   PMID:24376764   PMID:24621600   PMID:32007102  


Comparative Map Data
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
mRatBN7.237,111,567 - 7,127,451 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl37,111,550 - 7,127,445 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx310,225,656 - 10,231,090 (+)NCBIRnor_SHR
UTH_Rnor_SHRSP_BbbUtx_1.0318,811,887 - 18,817,327 (+)NCBIRnor_SHRSP
UTH_Rnor_WKY_Bbb_1.0317,001,698 - 17,007,132 (+)NCBIRnor_WKY
Rnor_6.031,449,778 - 1,468,624 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl31,452,644 - 1,468,614 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.031,445,598 - 1,461,452 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.432,607,800 - 2,613,216 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.132,607,803 - 2,611,842 (+)NCBI
Celera31,959,290 - 1,964,693 (+)NCBICelera
Cytogenetic Map3p13NCBI
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
GRCh382113,099,360 - 113,134,014 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p13 Ensembl2113,099,315 - 113,134,016 (+)EnsemblGRCh38hg38GRCh38
GRCh372113,875,548 - 113,891,591 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 362113,591,941 - 113,608,064 (+)NCBINCBI36Build 36hg18NCBI36
Build 342113,591,700 - 113,607,823NCBI
Celera2107,260,159 - 107,276,191 (+)NCBICelera
Cytogenetic Map2q14.1NCBI
HuRef2106,329,950 - 106,345,897 (+)NCBIHuRef
CHM1_12113,879,899 - 113,896,017 (+)NCBICHM1_1
T2T-CHM13v2.02113,544,556 - 113,560,594 (+)NCBIT2T-CHM13v2.0
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
GRCm39224,226,872 - 24,241,503 (+)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl224,226,865 - 24,241,506 (+)EnsemblGRCm39 Ensembl
GRCm38224,336,860 - 24,351,491 (+)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl224,336,853 - 24,351,494 (+)EnsemblGRCm38mm10GRCm38
MGSCv37224,192,380 - 24,207,011 (+)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv36224,158,869 - 24,173,490 (+)NCBIMGSCv36mm8
Celera224,056,294 - 24,070,923 (+)NCBICelera
Cytogenetic Map2A3NCBI
cM Map216.36NCBI
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
ChiLan1.0 EnsemblNW_0049554701,144,810 - 1,159,471 (-)EnsemblChiLan1.0
ChiLan1.0NW_0049554701,145,022 - 1,159,413 (-)NCBIChiLan1.0ChiLan1.0
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
NHGRI_mPanPan12A15,059,572 - 15,065,747 (-)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v02A88,991,646 - 89,008,013 (-)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.12A114,061,182 - 114,077,048 (+)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl2A114,061,182 - 114,078,839 (+)Ensemblpanpan1.1panPan2
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
CanFam3.11737,236,690 - 37,250,424 (+)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl1737,212,751 - 37,249,329 (+)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha1737,014,575 - 37,019,617 (+)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.01738,014,380 - 38,028,164 (+)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl1738,014,324 - 38,027,492 (+)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.11737,157,832 - 37,162,873 (+)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.01737,214,332 - 37,219,374 (+)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.01737,426,795 - 37,431,843 (+)NCBIUU_Cfam_GSD_1.0
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
HiC_Itri_2NW_02440629282,552,650 - 82,571,860 (+)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_0049367831,447,106 - 1,466,340 (+)EnsemblSpeTri2.0
SpeTri2.0NW_0049367831,447,158 - 1,466,331 (+)NCBISpeTri2.0SpeTri2.0SpeTri2.0
(Sus scrofa - pig)
No map positions available.
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
ChlSab1.11416,136,667 - 16,152,451 (+)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl1416,146,333 - 16,151,326 (+)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_0236660803,528,175 - 3,543,946 (-)NCBIVero_WHO_p1.0Vero_WHO_p1.0
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
HetGla_female_1.0 EnsemblNW_00462474913,210,476 - 13,225,890 (+)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_00462474913,210,365 - 13,224,471 (+)NCBIHetGla_female_1.0HetGla 1.0hetGla2


Variants in Il1rn
23 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:409
Count of miRNA genes:220
Interacting mature miRNAs:255
Prediction methods:Microtar, Miranda, Rnahybrid
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (
For more information about miRGate, see PMID:25858286 or access the full paper here.

QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
70202Alc19Alcohol consumption QTL 192.5drinking behavior trait (VT:0001422)ethanol intake volume to total fluid intake volume ratio (CMO:0001591)3127494778Rat
631679Cm10Cardiac mass QTL 107.340.0001heart left ventricle mass (VT:0007031)heart left ventricle weight to body weight ratio (CMO:0000530)3131158234Rat
631831Alc8Alcohol consumption QTL 82.7consumption behavior trait (VT:0002069)calculated ethanol drink intake rate (CMO:0001615)3133230976Rat
61468Bp15Blood pressure QTL 154.4blood pressure trait (VT:0000183)diastolic blood pressure (CMO:0000005)3133278763Rat
61468Bp15Blood pressure QTL 154.4blood pressure trait (VT:0000183)systolic blood pressure (CMO:0000004)3133278763Rat
61468Bp15Blood pressure QTL 154.4blood pressure trait (VT:0000183)pulse pressure (CMO:0000292)3133278763Rat
631545Bp85Blood pressure QTL 853.1arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)3133278763Rat
4889966Bss95Bone structure and strength QTL 954.4tibia area (VT:1000281)tibia-fibula cross-sectional area (CMO:0001718)3136847613Rat
2312664Scl62Serum cholesterol level QTL 620.05blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)3138710544Rat
631568Bp92Blood pressure QTL 922.20.005arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)3139874793Rat
2290452Scl56Serum cholesterol level QTL 562.26blood cholesterol amount (VT:0000180)plasma total cholesterol level (CMO:0000585)3191609953Rat
1358185Ept6Estrogen-induced pituitary tumorigenesis QTL 66.7pituitary gland mass (VT:0010496)pituitary gland wet weight (CMO:0000853)3653764510778823Rat
2292615Ept17Estrogen-induced pituitary tumorigenesis QTL 176.7pituitary gland mass (VT:0010496)pituitary gland wet weight (CMO:0000853)3653764510778823Rat

Markers in Region
Rat AssemblyChrPosition (strand)SourceJBrowse
Cytogenetic Map5q32UniSTS
Cytogenetic Map13q24UniSTS
Cytogenetic Map6q32UniSTS
Cytogenetic Map17p12UniSTS
Cytogenetic Map16p14UniSTS
Cytogenetic Map13q26UniSTS
Cytogenetic Map10q22UniSTS
Cytogenetic Map7q11UniSTS
Cytogenetic Map8q24UniSTS
Cytogenetic Map5q21UniSTS
Cytogenetic Map4q24UniSTS
Cytogenetic Map2q11UniSTS
Cytogenetic Map1q54UniSTS
Cytogenetic Map1q36UniSTS
Cytogenetic Map18p11UniSTS
Cytogenetic Map13q13UniSTS
Cytogenetic Map10q24UniSTS
Cytogenetic Map8q31UniSTS
Cytogenetic Map3q21UniSTS
Cytogenetic Map13p13UniSTS
Cytogenetic Map1q21UniSTS
Cytogenetic Map11q23UniSTS
Cytogenetic Map10q31UniSTS
Cytogenetic Map16q12.2UniSTS
Cytogenetic Map3q24UniSTS
Cytogenetic Map5q36UniSTS
Cytogenetic Map3p13UniSTS


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
Medium 2 22 22 10 22 4 10
Low 1 23 31 15 9 15 8 8 58 31 23 1 8
Below cutoff 14 4 4 4 3 8 4 13


Reference Sequences
RefSeq Acc Id: ENSRNOT00000007949   ⟹   ENSRNOP00000007949
RefSeq Status:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl37,111,550 - 7,127,445 (+)Ensembl
Rnor_6.0 Ensembl31,452,644 - 1,468,614 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000115274   ⟹   ENSRNOP00000088820
RefSeq Status:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl37,121,994 - 7,127,445 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000115476   ⟹   ENSRNOP00000088729
RefSeq Status:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl37,121,863 - 7,127,445 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000119822   ⟹   ENSRNOP00000081385
RefSeq Status:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl37,111,550 - 7,125,865 (+)Ensembl
RefSeq Acc Id: NM_022194   ⟹   NP_071530
Rat AssemblyChrPosition (strand)Source
mRatBN7.237,122,031 - 7,127,451 (+)NCBI
Rnor_6.031,463,208 - 1,468,624 (+)NCBI
Rnor_5.031,445,598 - 1,461,452 (+)NCBI
RGSC_v3.432,607,800 - 2,613,216 (+)RGD
Celera31,959,290 - 1,964,693 (+)RGD
RefSeq Acc Id: XM_006233636   ⟹   XP_006233698
RefSeq Status:
Rat AssemblyChrPosition (strand)Source
mRatBN7.237,111,567 - 7,127,451 (+)NCBI
Rnor_6.031,449,778 - 1,468,624 (+)NCBI
Rnor_5.031,445,598 - 1,461,452 (+)NCBI
RefSeq Acc Id: XM_006233637   ⟹   XP_006233699
RefSeq Status:
Rat AssemblyChrPosition (strand)Source
mRatBN7.237,121,856 - 7,127,451 (+)NCBI
Rnor_6.031,463,022 - 1,468,624 (+)NCBI
Rnor_5.031,445,598 - 1,461,452 (+)NCBI
RefSeq Acc Id: XM_039105774   ⟹   XP_038961702
RefSeq Status:
Rat AssemblyChrPosition (strand)Source
mRatBN7.237,117,074 - 7,127,451 (+)NCBI
Reference Sequences
RefSeq Acc Id: NP_071530   ⟸   NM_022194
- Peptide Label: precursor
- UniProtKB: P25086 (UniProtKB/Swiss-Prot)
- Sequence:
RefSeq Acc Id: XP_006233698   ⟸   XM_006233636
- Peptide Label: isoform X2
- UniProtKB: A0A0H2UHE2 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: XP_006233699   ⟸   XM_006233637
- Peptide Label: isoform X3
- Sequence:
RefSeq Acc Id: ENSRNOP00000007949   ⟸   ENSRNOT00000007949
RefSeq Acc Id: XP_038961702   ⟸   XM_039105774
- Peptide Label: isoform X1
RefSeq Acc Id: ENSRNOP00000088820   ⟸   ENSRNOT00000115274
RefSeq Acc Id: ENSRNOP00000081385   ⟸   ENSRNOT00000119822
RefSeq Acc Id: ENSRNOP00000088729   ⟸   ENSRNOT00000115476

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-P25086-F1-model_v2 AlphaFold P25086 1-178 view protein structure


eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

RGD ID:13691848
Promoter ID:EPDNEW_R2373
Type:multiple initiation site
Description:interleukin 1 receptor antagonist
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database,
Experiment Methods:Single-end sequencing.
Rat AssemblyChrPosition (strand)Source
Rnor_6.031,452,797 - 1,452,857EPDNEW

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:621159 AgrOrtholog
BioCyc Gene G2FUF-50507 BioCyc
Ensembl Genes ENSRNOG00000005871 Ensembl, ENTREZGENE, UniProtKB/TrEMBL
Ensembl Protein ENSRNOP00000007949 ENTREZGENE
  ENSRNOP00000007949.5 UniProtKB/TrEMBL
  ENSRNOP00000081385.1 UniProtKB/TrEMBL
  ENSRNOP00000088729.1 UniProtKB/TrEMBL
  ENSRNOP00000088820.1 UniProtKB/TrEMBL
Ensembl Transcript ENSRNOT00000007949 ENTREZGENE
  ENSRNOT00000007949.7 UniProtKB/TrEMBL
  ENSRNOT00000115274.1 UniProtKB/TrEMBL
  ENSRNOT00000115476.1 UniProtKB/TrEMBL
  ENSRNOT00000119822.1 UniProtKB/TrEMBL
Gene3D-CATH UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
InterPro IL-1_CS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  IL-1_fam UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  IL-1RA/IL-36 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  IL1/FGF UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
KEGG Report rno:60582 UniProtKB/Swiss-Prot
PANTHER PTHR10078 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  PTHR10078:SF28 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Pfam IL1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PhenoGen Il1rn PhenoGen
  INTRLEUKIN1X UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
SMART IL1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Superfamily-SCOP SSF50353 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL

Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2004-09-10 Il1rn  interleukin 1 receptor antagonist    interleukin 1 receptor antagonist gene  Name updated 1299863 APPROVED
2002-08-07 Il1rn  interleukin 1 receptor antagonist gene      Symbol and Name status set to provisional 70820 PROVISIONAL

RGD Curation Notes
Note Type Note Reference
gene_evolution sequence comparison depicts a gene duplication event between IL-1 alpha and beta as these three proteins have a common ancestor 633061
gene_protein has a beta stranded structure 633061